SLC5A2 and diabetic kidney disease: The aim of this review is to summarize the experimental evidence that supports or fails to support the nephroprotective efficacy of SGLT2 inhibitors in non-diabetic kidney diseases, and to describe at least some of the possible mechanisms involved in SGLT2 inhibitors-driven nephroprotection in the absence of hyperglycemia.